In immediate-release solid dosage development, 2,7-Dichloro-α-(Dibutylamino)methyl-9H-Fluorene-4-Methanol is handled as a low-aqueous-solubility free base whose dibutylamino substituent produces pH-dependent solubility in 0.1 N hydrochloric acid and poor flow after micronization. Direct compression is selected only when the incoming API lot has a laser-diffraction D90 below 30 µm, a bulk density between 0.40 g/mL and 0.55 g/mL, and a Hausner ratio no greater than 1.45. The blend consists of API at 5–25 wt%, microcrystalline cellulose PH102 at 45–65 wt%, spray-dried lactose monohydrate at 20–35 wt%, croscarmellose sodium at 2–4 wt%, colloidal silicon dioxide at 0.5–1.0 wt%, and magnesium stearate at 0.5–1.0 wt%. Blending is performed in a bin blender at 15–20 rpm for 20–25 min after a pre-lubrication step of 12 min. Tablets are compressed on a rotary press with B-tooling at 8–14 kN main compression force and a target crushing strength of 60–90 N. Friability is maintained below 1.0% according to USP <1216>, and content uniformity is measured by USP <905> with an acceptance value not exceeding 15.0. Dissolution is run in USP <711> Apparatus II at 75 rpm with 900 mL of 0.1 N hydrochloric acid containing 0.5% w/v polysorbate 80; Q-values above 75% at 45 min are typical for batches where the API D10 remains above 2 µm. Terminal use is a film-coated immediate-release tablet; film coating with Opadry II at 2.5–3.5% weight gain is applied in a perforated pan at 45–55°C exhaust temperature. Operational boundary: if the API lot has a D90 below 10 µm or loss on drying above 2.0%, direct compression is discontinued because die-filling variability and sticking on the upper punch are observed on production runs. Residual solvent content in the final core is controlled below ICH Q3C Option 2 limits because the API is isolated from an organic solvent system; the only solvent expected is acetone below 5,000 ppm.

What Homogenization Pressure Prevents Droplet Coalescence in Injectable Lipid Emulsions?

For an injectable lipid emulsion, the compound is dissolved in a mixture of medium-chain triglycerides and long-chain triglycerides rather than suspended. The oil phase is composed of MCT/LCT 1:1 w/w at 10% w/v, egg lecithin at 1.2% w/v, and α-tocopherol at 0.03% w/v; the aqueous phase contains glycerol 2.25% w/v in water for injection. Initial pre-emulsion is produced in a Silverson L5M-A rotor-stator mixer at 8,000–10,000 rpm for 10–15 min under nitrogen overlay. The coarse emulsion is then processed in a Microfluidics M-110P high-pressure homogenizer at 80–100 MPa for 5–8 discrete passes, with outlet temperature controlled to below 25°C by a chilled heat exchanger. Final mean droplet diameter is below 180 nm by dynamic light scattering, and the large-diameter tail is controlled by USP <729> PFAT5 with a limit below 0.05%. Terminal sterilization is by autoclaving at 121°C for 15 min; this requires pH adjustment to 6.0–8.0 before sterilization because pH drift above 8.5 is associated with lecithin hydrolysis and free fatty acid release. Osmolality is adjusted to 280–320 mOsm/kg per USP <785>, endotoxin is controlled below 0.5 EU/mg per USP <85>, and visible particulates are inspected per USP <790>. Terminal product is an injectable lipid emulsion supplied as a 10-mL single-dose unit. Operational boundary: the process should avoid cationic surfactants and divalent cations above 2 mM, since these reduce the zeta potential below −30 mV and promote Ostwald ripening on storage at 2–8°C. Filter integrity is retained with a bubble point above 3.4 bar for 0.22 µm PVDF per ASTM F838-20.

For pediatric dispersible tablet manufacture, the API is first transformed into taste-masked granules by fluid-bed top-spray coating before compression, because the tertiary amine contributes bitterness at oral contact. A binder-spray granulation using mannitol and low-substituted hydroxypropyl cellulose is performed in a Glatt GPCG 3.1 with inlet air at 55–65°C, spray rate 12–20 g/min, atomization pressure 1.5 bar, and product temperature maintained at 32–38°C. The granulate is sieved to 500 µm and then seal-coated with ethylcellulose aqueous dispersion at 10–15% weight gain for bitter taste suppression; granule moisture after drying is held below 1.5% w/w. The coated granules are blended with crospovidone 3–5%, sodium stearyl fumarate 1.0%, and a sucrose-free sweetener 2–4%. Tablets are compressed at 4–8 kN to a hardness of 25–35 N, producing a 250 mg dispersible unit. Disintegration is measured at 37°C in 40 mL purified water per Ph. Eur. 2.9.1, with complete dispersion required below 3 min. Content uniformity is assessed by USP <905>, and dissolution in 0.1 N hydrochloric acid with 0.5% w/v polysorbate 80 must exceed 80% at 30 min. Terminal product is a pediatric dispersible tablet packaged in cold-form foil blister; the primary packaging must have a water vapor transmission rate below 0.05 g/m²/day because the uncoated granules are hygroscopic above 60% relative humidity.

When Roller Compaction Replaces Aqueous Wet Granulation for High-Dose Tablet Cores

When aqueous wet granulation is not tolerated because of hydrolysis risk in prolonged wet massing, roller compaction is selected to densify the compound without adding water. The API is pre-blended with microcrystalline cellulose PH102 at 15–25% and crospovidone at 3–5%; colloidal silicon dioxide at 0.5% is included to reduce sticking to the rolls. Roller compaction is run on a Gerteis Mini-Pactor with roll force 6–10 kN/cm, gap 2–3 mm, and roll speed 2–4 rpm. Ribbons are milled through an oscillating screen of 0.8 mm to 1.5 mm, and the granule fraction between 125 µm and 800 µm is collected. Extragranular crospovidone 2–3%, microcrystalline cellulose PH102 8–12%, and sodium stearyl fumarate 1.0% are added before final compression. The high-dose cores are compressed on a rotary press with D-tooling at 15–25 kN, yielding tablet weights of 800–1,000 mg and hardness 100–150 N. Dissolution is measured by USP <711> Apparatus I at 100 rpm in 900 mL of 0.1 N hydrochloric acid containing 0.5% w/v cetyltrimethylammonium bromide; the acceptance criterion is not less than 70% at 60 min. Terminal product is a high-dose tablet core intended for subsequent film coating with a hypromellose-based system in a side-vented pan at 50–60°C exhaust temperature. Process limitation: the granule solid fraction should remain between 0.58 and 0.72; ribbons below 0.55 solid fraction generate excessive fines above 35% and require rejection of the compaction batch.

Torque and Residence Time Boundaries in Hot-Melt Extruded Dispersions

Hot-melt extrusion converts the crystalline API into an amorphous solid dispersion only when the screw configuration and barrel temperature profile maintain a residence time between 45 s and 120 s. The compound is pre-blended with Kollidon VA64 at 30–50 wt%, Soluplus at 20–30 wt%, and polyethylene glycol 4000 at 5–10 wt%. Extrusion is performed on a Leistritz ZSE 18 HP twin-screw extruder with an L/D ratio of 40, screw speed 150–250 rpm, and a barrel profile from 130°C to 160°C. Torque is held from 35% to 55% of the drive rating; excursions above 60% are associated with melt fracture at the die and nonuniform strand diameter. Melt temperature at the die is monitored with an infrared probe and controlled below 165°C, since discoloration of the dibutylamino moiety is observed above this threshold in extended runs. Extrudate strands are cooled on a belt conveyor, pelletized at 1.0–1.5 mm, and milled with a sieve of 500 µm. Residual crystallinity is determined by X-ray powder diffraction with a detection limit of 2%; batches with measurable crystalline peaks are rejected because seeding during storage reduces dissolution. The amorphous milled extrudate is filled into hard gelatin or HPMC capsules at 250–500 mg fill weight on a Bosch GKF 2000 capsule filler with a tamping pin setting of 10 mm. Dissolution in fasted-state simulated intestinal fluid is evaluated by USP <711> Apparatus II with 500 mL FaSSIF at 37°C and 75 rpm; Q-values above 70% at 120 min are considered process-acceptable. Terminal product is a hard capsule containing an amorphous solid dispersion; the capsules are stored in HDPE bottles with desiccant because relative humidity above 35% at 25°C causes moisture-induced recrystallization within 8 weeks.

A Lyophilized Cyclodextrin Complex Is Prepared Only Below Its Collapse Temperature

Because the free base form has poor aqueous solubility, a lyophilized injectable intermediate is prepared through cyclodextrin complexation when an aqueous intravenous presentation is required. The API is combined with sulfobutylether-β-cyclodextrin at a molar ratio of 1:2 to 1:5 in a solution of citric acid adjusted to pH 3.0–4.0; sodium chloride is added to reach an osmolality of 280–320 mOsm/kg after reconstitution. The bulk solution is filtered through a 0.22 µm PVDF membrane into sterile 10-mL vials. Lyophilization is performed with a primary drying shelf temperature of −20°C for 36–48 h, followed by secondary drying at 25°C for 8–12 h; chamber pressure is maintained at 0.2–0.5 mbar. The collapsed temperature of the formulation is estimated to be below −15°C, so primary drying above this value is not permitted. The lyophilized cake is reconstituted with water for injection to a final API concentration of 2–5 mg/mL; complete dissolution should occur within 2 min without visible particles per USP <790>. Particulate matter after reconstitution is assessed by USP <788>: limits are 6,000 particles/container for ≥10 µm and 600 particles/container for ≥25 µm. Bacterial endotoxin is controlled below 0.5 EU/mg per USP <85>. Terminal product is a lyophilized powder for intravenous injection after reconstitution. Published data for this specific cyclodextrin inclusion configuration is limited, so the molar ratio and pH window require verification against phase-solubility studies in the sponsor’s filing.